Clinical Benefit of Enoxaparin in Patients With High-Risk Acute Coronary Syndromes Without ST Elevations in Clinical Practice

摘要: In randomized clinical trials, low-molecular-weight heparin enoxaparin has been shown to decrease ischemic complications in patients with acute coronary syndromes (ACSs) without ST elevations who are treated conservatively. Enoxaparin be equally effective as unfractionated high-risk an early invasive approach. Little is known about the use and efficacy of unselected non–ST-elevation ACSs practice. a retrospective analysis prospective ACOS registry, we compared outcome were >60 years age myocardial infarction or unstable angina ST-segment changes heparin. total, 4,806 (55%) ACS fulfilled our inclusion criteria for this analysis; 1,178 (25%) 3,628 (75%) There no differences between groups baseline characteristics. We observed significant combined end point death nonfatal reinfarction entire study group (odds ratio 0.51, 95% confidence interval 0.37 0.70) subgroups percutaneous intervention (n = 1,333, odds 0.36, 0.17 0.80), artery bypass grafting during index hospitalization 270, 0.31, 0.04 2.42), conservatively 3,203, 0.57, 0.40 0.81). was increase severe bleeding (5.2% vs 4.5%). conclusion, practice, intervention, treatment associated in-hospital reinfarction, complications.